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Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of
acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clini-
cal trials have used discontinuous rather than continuous dosing of dexamethasone in an
effort to reduce the incidence of osteonecrosis. However, it is not known whether discontin-
uous dosing would compromise antileukemic efficacy of glucocorticoids. Therefore, we
tested the efficacy of discontinuous dexamethasone against continuous dexamethasone in
murine models bearing human acute lymphoblastic leukemia xenografts (n = 8 patient sam-
ples) or murine BCR-ABL+ acute lymphoblastic leukemia. Plasma dexamethasone concen-
trations (7.9 to 212 nM) were similar to those achieved in children with acute lymphoblastic
leukemia using conventional dosages. The median leukemia-free survival ranged from 16
to 59 days; dexamethasone prolonged survival from a median of 4 to 129 days in all seven
dexamethasone-sensitive acute lymphoblastic leukemias. In the majority of cases (7 of 8
xenografts and the murine BCR-ABL model) we demonstrated equal efficacy of the two
dexamethasone dosing regimens; whereas for one acute lymphoblastic leukemia sample,
the discontinuous regimen yielded inferior antileukemic efficacy (log-rank p = 0.002). Our
results support the clinical practice of using discontinuous rather than continuous dexa-
methasone dosing in patients with acute lymphoblastic leukemia.
Introduction
With increasing intensity of treatment to improve the cure rates for acute lymphoblastic leuke-
mia (ALL), toxic complications of chemotherapy have also increased. The incidence of
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osteonecrosis is high; 18% of patients experienced symptomatic osteonecrosis in one prospec-
tive study,[1] although others have reported rates between 1–25%.[2–8] Osteonecrosis is
defined as bone death resulting from poor blood supply.[9] The development of osteonecrosis
has been associated with the intensity of the drug exposure, type of steroid
(dexamethasone> prednisone),[5] age, gender, asparaginase antibodies,[10] and genetics.[1,
11] Our group demonstrated that the initiating lesion in the mouse model of glucocorticoid-
induced osteonecrosis is likely arteriopathy within the vessels supplying the distal femur.[12]
Dexamethasone may contribute to osteonecrosis via its effects on lipids, coagulation, fibrinoly-
sis, and direct toxic effects on vasculature and bone.[13, 14]
The Children’s Oncology Group trial CCG-1961 found that osteonecrosis was more com-
mon in the group receiving continuous dosing of dexamethasone versus those receiving dis-
continuous (alternate week) dexamethasone despite lower cumulative doses,[15, 16] with no
reported loss of efficacy with discontinuous versus continuous dexamethasone when used in
the context of a second delayed intensification phase. However, the efficacy assessment was
complicated by the additional vincristine, anthracycline, and asparaginase given during an
additional course of reinduction.[15, 16] Many ALL clinical trials now include a discontinuous
glucocorticoid schedule, in which patients receive dexamethasone daily for 5–8 days, none for
a period of some days, and then daily again, in an attempt to reduce the incidence of osteone-
crosis, without evidence on whether discontinuous and continuous dexamethasone dosing
have equivalent antileukemic effect.
Using a murine model of osteonecrosis, our group previously found that mice treated with a
discontinuous regimen of dexamethasone developed less osteonecrosis than those treated with
a continuous regimen,[17] consistent with clinical data in ALL [15, 16] and systemic lupus ery-
thematosus patients.[18] Herein, we compared the antileukemic efficacy of these same dexa-
methasone regimens in a murine BCR-ABL Arf-/- preB cell ALL model in two different strains
of mice [19] and in xenograft models of eight different primary ALL samples.
Materials & Methods
Murine leukemia cells
BCR-ABL (p185+) luciferase-positive cell lines were generated from bone marrow of Arf-/-
mice on the C57Bl/6J and 129X1SvJ backgrounds as described previously.[19–21] Cells were
thawed and recovered in culture for three days prior to intravenous tail vein injection of 2x103
cells into non-irradiated male 8-week old matched syngenic mice (C57Bl/6 or 129X1SvJ, Arf-
wildtype).
Passage and transduction of patient leukemia cells
Bone marrow aspirates were cryopreserved at the time of ALL diagnosis by the St. Jude Tissue
Resources Lab and kept at -140°C. Patient demographic details can be found in S1 Table. Writ-
ten informed consent was obtained from patients or their parents/guardians, and assent from
the patients, as appropriate. The consent, research and use of these samples were approved by
the St. Jude Children’s Research Hospital Institutional Review Board on protocol XPD10-102.
Patient samples were thawed, washed and injected via tail vein (1–5 million cells per mouse)
into non-irradiated 8 week old female NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. The sam-
ples were passaged serially through NSG mice. Bone marrow isolated from the first passage
was transduced with a lentiviral vector containing YFP and luciferase for the second passage,
sorted for YFP+ cells prior to the third passage, and tested for in vivo efficacy of continuous
and discontinuous dexamethasone dosing on the fourth passage.
Discontinuous Dexamethasone Efficacy in ALL Xenografts
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When leukemia was evident in the blood of the first passage in mice by flow cytometry for
hCD45 (see below), mice were sacrificed and bone marrow was isolated by flushing the femurs
and tibias of each mouse with RPMI-1640 (Lonza BioWhittaker, Walkersville, MD) supple-
mented with 10% FBS (Thermo Scientific Hyclone, Logan, UT) and 2 mM L-glutamine (Lonza
BioWhittaker, Walkersville, MD). The marrow was macerated over a sterile cell strainer
(40 μmmesh) before counting cells with the Nexcelom Cellometer Vision, using the acridine
orange propidium iodide (AOPI) assay (Nexcelom Bioscience LLC, Lawrence, MA). Non-tis-
sue culture treated plates (Becton Dickinson Labware, Franklin Lakes, NJ) were coated with 20
ug/mL RetroNectin (Takara Bio Inc, Shiga, Japan) for 2 hours. Lentivirus encoding firefly lucif-
erase and yellow fluorescent protein (CL20SF2-Luc2aYFP with VSV-G envelope, St. Jude Chil-
dren’s Research Hospital Vector Lab, Memphis, TN) was mixed with bone marrow cells at a
multiplicity of infection of 50 in IMDM + Glutamax media (GIBCO, Grand Island, NY) con-
taining 20 ng/mL hIL-3 (Peprotech, Rocky Hill, NJ), 10 ng/mL hIL-7 (Peprotech), 50 ng/mL
hSCF (Peprotech), 20 ng/mL hFLT3L (Peprotech), 2% human albumin (Sigma-Aldrich,
St. Louis, MO), 1x ITS (10 mg/L insulin, 5.5 mg/L transferrin, 6.7 ug/L selenious acid, Cellgro,
Manassas, VA), at a concentration of 1.13 x 106 cells/mL. The plate was incubated at 37°C, and
was swirled every 2 hours. The media was removed and replaced after 6 hours, and the plate
incubated overnight at 37°C. The cells were dissociated from the retronectin with PBS + 0.02%
EDTA, washed three times with PBS and reinjected into recipient NSG mice via tail vein.
At the second passage, when leukemia was evident in the blood by flow cytometry or by
Xenogen imaging (see below), the mice were sacrificed and bone marrow harvested as above
and sorted for YFP and a human cell surface marker (hCD45, hCD7, or hCD19, depending on
the sample). Following the sort, the cells were centrifuged at 300g, resuspended in PBS and
reinjected into NSG mice.
The bone marrow was harvested from the third passage for immediate reinjection into NSG
mice for the efficacy experiments (fourth passage) and MTT assay (see below).
Mice
Unconditioned mice were seven to nine weeks old at the time of leukemia injection. Mice were
observed daily and sacrificed when leukemia cells reached 50% in the peripheral blood, lumi-
nescence was nearing saturation, or they displayed clinical symptoms (hind limb paralysis, ruf-
fled fur, respiratory distress, poor mobility), depending on the model. This study was carried
out in strict accordance with the recommendations in the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. Mice were housed in an American Associa-
tion of Laboratory Animal Care—accredited facility and were treated using a protocol
approved by the St. Jude Animal Care and Use Committee (Protocol Number: 465–100202) in
accordance with National Institutes of Health guidelines. Mice were purchased from The Jack-
son Laboratory: C57Bl/6J (000664), 129X1SvJ (000691), NSG (005557) and maintained under
specific pathogen-free conditions. Animals were sacrificed by carbon dioxide asphyxiation,
using a gradual displacement method, consistent with the American Veterinary Medical Asso-
ciation Guidelines for the Euthanasia of Animals: 2013 Edition. All efforts were made to mini-
mize suffering.
Dexamethasone & Corticosterone LC-MS
During dexamethasone treatment, blood was drawn twice weekly, just prior to the change of
medicated water for measurement of dexamethasone and corticosterone. Dexamethasone and
corticosterone plasma concentrations were measured using liquid chromatography with tan-
dem mass spectrometric detection (see supplement for details).
Discontinuous Dexamethasone Efficacy in ALL Xenografts
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Ex vivoMTT assay
Leukemia cells from bone marrow aspirates were tested for drug sensitivity at diagnosis of
ALL, as described [22] (details in Supplement). Xenograft bone marrow samples were treated
similarly, although some were incubated fewer than 96 hours. If an LC50 value could not be
estimated due to resistance, it was set as twice the highest concentration tested for the purpose
of statistical analysis. All xenograft bone marrow samples were depleted of mCD45+ cells with
magnetic separation prior to plating, according to manufacturer’s protocol (Miltenyi auto-
MACS and mCD45 microbeads, #130-052-301 Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany). We selected seven samples that were sensitive to nanomolar concentrations and
one dexamethasone resistant sample which had an LC50>15 uM to test the efficacy of contin-
uous and discontinuous dexamethasone dosing in vivo.
In vivo treatment
Treatment was started 3–28 days after tail vein injection of leukemia, depending on the speed
of engraftment and progression of leukemia in the absence of treatment (Table 1). Mice were
randomized to a treatment group based on the ventral luminescence, so all treatment group
medians for luminescence were similar at start of therapy (p>0.1 by t test). Two dexametha-
sone treatment regimens were tested for antileukemic efficacy: continuous dexamethasone
given at 4 mg/L in the drinking water, or discontinuous dexamethasone given at 8 mg/L in the
drinking water for 3.5 days, followed by no dexamethasone for 3.5 days. Thus, total weekly
dose of dexamethasone was equivalent between the two treatment groups. Sulfamethoxazole
(600 mg/L) and trimethoprim (120mg/L; from Hi-Tech Pharmacal, Amityville, NY) was added
to the drinking water for half the week; tetracycline (1 g/L, Sigma-Aldrich, St. Louis, MO) was
always present. Dexamethasone sodium phosphate solution was obtained from American
Pharmaceutical Partners, Inc. (Schaumburg, IL). Water bottles were changed twice weekly for
all treatment groups. Assuming 5 mL intake per day [17], the discontinuously treated mice
would receive 1.6–2 mg/kg/day, which is equivalent to 4.8 to 6 mg/m2/day in a child based on a
body surface area conversion.[23] The continuously treated mice would receive 0.8–1 mg/kg/
day, equivalent to 2.4 to 3 mg/m2/day in a child. Mice were sacrificed when they became mori-
bund for any reason. Treatment time varied by patient sample (Table 1). Dexamethasone treat-
ment in all animals on an experiment was stopped when toxicity reached an unacceptable level
(SJE2A007) or the bioluminescent signal decreased to baseline levels in both dexamethasone
treatment groups (SJTALL030, SJBALL215, SJMLL005, SJMLL009, see S1 Fig for example).
Treatment was always ended at the end of a full week of treatment, so that the same total dose
was administered in the two regimens for each xenograft.
Bioluminescent imaging
In vivo imaging was performed with the Xenogen IVIS-200 3–5 minutes post IP injection of
100 mg/kg D-Luciferin (Caliper Life Sciences, Hopkinton, MA). The mice were anesthetized
by isoflurane (2–3% in oxygen) prior to imaging. Images were acquired with small binning,
beginning at one minute exposure, or less if images were saturated. Images were analyzed with
Living Image 4.0 software (Caliper Life Sciences, Hopkinton, MA). Total flux measurements
(photons/second) were quantified over the whole animal.
Flow cytometry
Blood was collected from the retro-orbital sinus, facial vein, or tail vein of anesthetized mice to
assess engraftment of human cells. Blood was lysed with the BD FACS Lyse Wash Assistant
Discontinuous Dexamethasone Efficacy in ALL Xenografts
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(BD Biosciences, San Jose, CA). Cells were stained with antibodies to human CD45 (BD Biosci-
ences, # 561864, APC), mouse CD45 (BD Biosciences, # 559864, PE). Samples were assayed on
the BD LSR II or LSR Fortessa (BD Biosciences) and data were analyzed with FlowJo version 9
(FlowJo, LLC, Ashland, OR). Samples were sorted for hCD45 and YFP on the BD Aria (BD
Biosciences).
Leukemia-free survival
Mice receiving xenografts generally did not develop overt symptoms of leukemia prior to sacri-
fice, so the endpoint for leukemia-free survival was based on leukemic burden determined by
either flow cytometry or luminescence. For samples that were not reliably detected in the
peripheral blood, a luminescence threshold was used as the endpoint. For samples reliably
detectable in the blood, an hCD45+ threshold was used as the endpoint (either 25% or 50% of
Table 1. Median leukemia-free survival (LFS) and growth delay factor (GDF) for eachmurine model.



































3–58 NA 11.1 10 16 16–21 20 30 21–42 14 20 30 23–36 14 0.5 0.0008 0.0009
SJTALL021916 14–
56
0.4 23 11 27 14–32 21 37 20–56 10 22 31 21–50 4 0.2 0.002 0.011
SJTALL033 7–50 2.9 330 5 22 21–25 10 38 35–45 16 10 37 33–49 15 0.9 0.019 0.021
SJTALL030 14–
35
5.1 3.1 5 59 51–86 10 95 71–
109
36 10 80 64–
122
21 0.7 0.031 0.064
SJMLL005 21–
56
4.9 27 10 27 16–34 20 153 38–
160
126 20 156 71–
157
129 0.14 0.00003 0.0001
SJBALL215 28–
98
0.7 50 5 53 38–65 10 NA 134 * 10 144 128–
194
91 0.15 0.00065 0.016
SJE2A007 21–
91
4.5 32 4 49 46–51 10 111 110–
114
62 10 77 63–
112
28 0.002 0.001 0.033
SJMLL009 21–
42
35.3 3.2 5 27 26–27 10 NA 93–
108
* 10 106 88–
109
79 0.22 0.0033 0.011
SJHYPO123 21–
49
>15,000 >15,000 9 42 40–44 8 46 43–53 4 8 43 40–47 1 0.066 0.004 0.21
Cont dex: mice treated continuously with 4 mg/L dexamethasone. Disc dex: mice treated discontinuously with 8 mg/L dexamethasone for half of each
week. N, number of mice per treatment group. LFS, median leukemia-free survival. LFS, Range, and GDF are shown in days. Dex days indicates the
days the mice were treated with dexamethasone, with the injection of leukemia being day 0 (the same total dose was administered in the two regimens for
each xenograft). LC50-D indicates the dexamethasone LC50 in the patient bone marrow at the time of ALL diagnosis. LC50-X indicates the
dexamethasone LC50 in the xenograft bone marrow from the passage prior to the efficacy experiment or in the case of the mouse cell lines, the passage
that was injected into the mice. Details on the calculation of LFS and GDF are found in the methods. NA indicates that the median LFS could not be
calculated because of too few leukemic events.
* indicates that the GDF was not calculated because the median LFS was not calculated.
doi:10.1371/journal.pone.0135134.t001
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cells in the live lymphocyte gate). The leukemia endpoint was hCD45>50% in the live lympho-
cyte gate for SJTALL021916, SJTALL033, SJTALL030, SJE2A007 and hCD45>25% for
SJHYPO123. The leukemia endpoint for SJMLL009 and SJBALL215 was ventral luminescence
>1010 p/s, and for SJMLL005, it was 5 x 108 p/s, based on the peak signal in the no dexametha-
sone group. Mice receiving the BCR-ABL+ Arf-/- ALL developed hind limb paralysis, and the
onset of this or other overt symptoms was used as the endpoint. Mice were censored from the
analysis if they were moribund for other reasons, such as infection or accidental death.
Statistical Analysis
Statistical analysis was performed using Statistica 11 (Statsoft, Inc, Tulsa, OK), R version 3.1.1
(www.r-project.org) or GraphPad Prism version 5.02. Leukemia-free survival was compared
using the log-rank test. The growth delay factor (GDF) was estimated by subtracting the
median survival of the untreated group from that of each treated group. Spleen weights and
LC50 values were compared with the MannWhitney test. P values less than 0.05 were consid-
ered statistically significant and were not adjusted for multiple comparisons.
Results
For all dexamethasone-sensitive xenograft samples, there was improved leukemia-free survival
(LFS) with at least one of the dexamethasone treatment regimens compared to no dexametha-
sone treatment (median LFS +4 to +129 days relative to no dexamethasone, log-rank p = 0.064
to p = 0.00003, Fig 1, Table 1). The dexamethasone-resistant sample did not have improved
LFS with discontinuous dexamethasone (p = 0.21, +1 day), but did with continuous dexameth-
asone (p = 0.004, +4 days), although this small improvement in survival is likely biologically
insignificant. Four of the samples reached the leukemic endpoint during dexamethasone treat-
ment (SJTALL021916, SJTALL033, SJE2A007, and SJHYPO123), while the others reached this
endpoint only after dexamethasone was stopped (e.g. SJMLL009, S1 Fig).
The murine C57Bl/6J and 129X1SvJ Arf-/- BCR-ABL preB cell lines were sensitive to dexa-
methasone, with LC50s of 9.2 (±0.6), and 11.1 (±0.6) nM, respectively (S2 Fig). LFS was
improved with dexamethasone compared to no dexamethasone (median LFS +30 to +46 days,
p<0.01 for all comparisons). There was equivalent efficacy of the two dexamethasone regimens
in both murine BCR-ABL strains (p = 0.5 and p = 1.0, respectively), which were significant
improvements over no dexamethasone treatment (Fig 2, Table 1). Both strains reached the leu-
kemic endpoint during dexamethasone treatment. The growth delay factors (GDF) were simi-
lar for the continuous and discontinuous regimens in the murine BCR-ABL model for both the
C57Bl/6J and 129X1SvJ strains, but differed between strains (28–30 days for C57Bl/6J and 14
days for 129X1SvJ, Table 1).
For seven of the eight xenograft samples, including the dexamethasone resistant sample,
there were no significant differences in LFS between the continuous and discontinuous regi-
mens (median LFS differed by 1–15 days, log-rank p = 0.066 to 0.9, Table 1 & Fig 1). For one of
the eight samples (SJE2A007), the continuous dexamethasone was more effective than the dis-
continuous schedule (median LFS of 111 vs 77 days, log-rank p = 0.002). In a second experi-
ment with the same sample, all the mice were sacrificed on the same day from start of therapy.
ALL burden was lower in the continuous dexamethasone group than the discontinuous dexa-
methasone group as assessed by ventral luminescence (Kruskal-Wallis p = 0.004, Fig 3A, S3
Fig), hCD45% in the peripheral blood (Kruskal-Wallis p = 0.007, Fig 3B) and by spleen size
(Kruskal-Wallis p = 0.006, Fig 3C). For two of the three T cell ALL samples (SJTALL021916
and SJTALL033), there was a cyclical pattern in the luminescence of the discontinuously
Discontinuous Dexamethasone Efficacy in ALL Xenografts
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Fig 1. Antileukemic efficacy of continuous, discontinuous, and no dexamethasone for xenografted
patient ALL samples. Red indicates continuous dexamethasone (Cont dex), green indicates discontinuous
dexamethasone (disc dex), and blue indicates no dexamethasone. Squares on the curve indicate leukemic
events, and + indicates censoring due to toxicity, accidental death, or the end of the experiment. Red and
green boxes indicate treatment period—red indicates continuous dexamethasone (4 mg/L) and green
indicates discontinuous dexamethasone (8 mg/L for 3.5 days, 0 for 3.5 days). P-values shown were
Discontinuous Dexamethasone Efficacy in ALL Xenografts
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treated group, in which it increased during the steroid holiday and decreased or remained con-
stant during the time the dexamethasone was in the drinking water (Fig 3A).
The ex vivo sensitivity was tested after in vivo dexamethasone treatment for six of the eight
xenograft samples (Fig 4). The remaining two samples were not tested because of poor viability
ex vivo (SJE2A007,<50% viable at 2 days ex vivo) or lack of sensitivity ex vivo (SJHYPO123,
LC50>15uM). The ex vivo sensitivity to four days of dexamethasone of the xenograft samples
pre-treatment or with no dexamethasone treatment was similar to that measured in the origi-
nal diagnosis sample in the majority of cases tested, however, this comparison is complicated
by the fact that the duration of the exposure to dexamethasone had to be reduced in some of
the xenograft samples that didn’t survive well in vitro for four days. The SJMLL005 sample
may have been more resistant after multiple passages in vivo, but it was tested for only two
days in vitro versus four days for the diagnosis sample. The SJTALL021916 cells were more
resistant ex vivo after in vivo dexamethasone treatment (within the same passage), and the leu-
kemic cells recovered from continuously treated mice had higher LC50s than those recovered
from the discontinuously treated animals (63.2 nM vs 34.6 nM, p = 0.02), which were both
higher than the leukemic cells from the mice receiving no dexamethasone (10.5 nM, both
p<0.01). The SJTALL033 cells were more resistant ex vivo after in vivo dexamethasone treat-
ment (both p<0.02 when compared with the mice receiving no dexamethasone in the same
passage, 47.3 nM), although the discontinuously treated mice had higher LC50s than the con-
tinuously treated mice (169 vs 107 nM, p = 0.04). The SJTALL030 cells had LC50s in the 20–30
nM range, after discontinuous or continuous therapy) as well as from the mice receiving no
dexamethasone. SJMLL005 cells also appeared more resistant to dexamethasone ex vivo after
in vivo dexamethasone treatment, though the cells from the dexamethasone-treated mice did
not reach 50% of the control viability, so an LC50 was not calculated. The SJMLL009 cells from
all treatment groups had similar LC50s, although the trend was for higher values in the dexa-
methasone-treated animals versus no dexamethasone. The SJBALL215 cells from dexametha-
sone-treated mice had lower LC50s than the mice that received no dexamethasone (17 nM vs
28 nM, p = 0.007).
Plasma concentrations of dexamethasone in mice on treatment were similar to plasma levels
(20–200 nM) achieved in patients treated for ALL [24] (Fig 5). On days that dexamethasone
was included in the drinking water of the discontinuously dosed mice, dexamethasone concen-
trations were higher in the discontinuously treated group than the continuously treated group
(Fig 5A), which was expected since the concentration in the discontinuously treated drinking
water was twice the concentration in the continuously treated group (8 mg/L vs 4 mg/L). The
SJTALL033 cells proliferated in vivo through dexamethasone treatment (Fig 1), and the ex vivo
sensitivity assay demonstrated LC50 levels at or above the mean plasma concentration (Figs 4
and 5). On days that the dexamethasone was not included in the drinking water, corticosterone
levels in the discontinuously treated group were lower than the no dexamethasone group, indi-
cating the corticosterone levels had not completely recovered in 3.5 days off therapy (Fig 5B).
Dexamethasone concentrations were not detectable in the mice on the discontinuous regimen
after 3.5 days off therapy. The mice receiving continuous dexamethasone had plasma dexa-
methasone concentrations of 40–90 nM, and undetectable levels of corticosterone at all time
points after dexamethasone treatment began, whereas mice in the discontinuous regimen had
some recovery of corticosterone during dexamethasone holidays.
calculated with the log-rank test, comparing the continuous and discontinuous dexamethasone treatment
arms, see Table 1 for comparisons of dexamethasone vs no dexamethasone.
doi:10.1371/journal.pone.0135134.g001
Discontinuous Dexamethasone Efficacy in ALL Xenografts
PLOS ONE | DOI:10.1371/journal.pone.0135134 August 7, 2015 8 / 18
Fig 2. Anti-leukemic survival was equivalent between dexamethasone treatment regimens in the
murine ALLmodel.Mice of the 129X1SvJ strain (A) and C57Bl/6 strain (B) were injected with Arf-/-
BCR-ABL+ luciferase+ leukemia and treated with continuous (Cont dex, red), discontinuous dexamethasone
(Disc dex, green), or no dexamethasone (blue) regimens. Boxes indicate leukemic events, while + indicates
censored events. P-values indicated are log-rank p-values comparing the continuous and discontinuous
dexamethasone regimens, see Table 1 for comparisons of dexamethasone vs no dexamethasone.
doi:10.1371/journal.pone.0135134.g002
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Fig 3. Continuous dexamethasone wasmore effective than discontinuous dexamethasone for SJE2A007 cells but not SJTALL021916 cells.Red
indicates continuous dexamethasone (Cont dex), green indicates discontinuous dexamethasone (disc dex), and blue indicates no dexamethasone. A,
ventral luminescence over time. Symbols indicate median luminescence and error bars indicate interquartile range. Red and green boxes near the x-axis
indicate treatment period (continuous dexamethasone in red, discontinuous dexamethasone in green). B, hCD45% in the blood over time. Symbols indicate
median and error bars indicate interquartile range. C, spleen weight on day 62 (SJE2A007, left) or at the time of sacrifice (SJTALL021916, right). Symbols
indicate individual mice, and horizontal line indicates median. P values were calculated with a two-tailed MannWhitney test.
doi:10.1371/journal.pone.0135134.g003
Discontinuous Dexamethasone Efficacy in ALL Xenografts
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Fig 4. Leukemia cells generally became less sensitive to dexamethasone after in vivo treatment. Dexamethasone sensitivity of leukemic bone marrow
cells at diagnosis (orange), the passage prior to in vivo treatment (purple), or at the time of sacrifice after in vivo treatment (continuous dexamethasone, red;
discontinuous dexamethasone, green; no dexamethasone, blue). Symbols indicate individual mice, the horizontal line indicates the mean, and error bars
indicate standard error of the mean (SEM). Incubation time for all diagnosis samples in the MTT assay was 4 days. Incubation time for cells from the mice
receiving continuous dexamethasone, discontinuous dexamethasone, and no dexamethasone was 4 days for SJTALL021916, SJTALL033, SJBALL215, 3
days for SJTALL030, and 2 days for SJMLL005 and SJMLL009. Ex vivo sensitivity was not tested in SJE2A007 due to poor viability after two days ex vivo
(<50%), and SJHYPO123 due to resistance of the sample at the time of diagnosis (LC50 > highest concentration tested, 15 uM, which was recapitulated in
the xenograft sample prior to in vivo treatment).
doi:10.1371/journal.pone.0135134.g004
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Discussion
Because the cumulative incidence of symptomatic osteonecrosis in ALL patients can be as high
as 10–20%,[1–7] efforts should be made to minimize treatment-related risk factors that may
induce osteonecrosis without compromising antileukemic efficacy. Previously, we’ve shown
that the incidence of osteonecrosis is less in mice receiving dexamethasone discontinuously
versus continuously,[17] supporting the clinical findings that discontinuous dexamethasone
Fig 5. Plasma dexamethasone concentrations in mice during treatment were similar to those
achieved in patients and corticosterone was suppressed in dexamethasone treatedmice. Plasma
dexamethasone (A) and corticosterone concentrations (B) in mice engrafted with SJTALL033 cells. Blue
shaded area indicates the concentration of dexamethasone found in patient samples (20–200 nM). Plasma
dexamethasone (dex) concentrations were determined by LC-MS twice weekly, just prior to the change of
medicated water. N = 10 in the dexamethasone treatment groups and N = 5 in the untreated controls (no dex
group). Treatment began on day 7 after plasma was taken, and is indicated by the boxes below the x-axis.
Green indicates discontinuous dexamethasone and red indicates continuous dexamethasone.
Dexamethasone was in the drinking water of the discontinuous (disc) dexamethasone group from day
7–10.5, 14–17.5, 21–24.5, 28–31.5, and 35–39.5. Bar height indicates mean and error bars indicate standard
error of the mean (SEM).
doi:10.1371/journal.pone.0135134.g005
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treatment is associated with lower risk of osteonecrosis. However, the impact of discontinuous
dexamethasone on antileukemic efficacy has heretofore not been evaluated. Others have previ-
ously shown the clinical relevance of ALL xenograft models by demonstrating that the time to
engraftment is correlated with relapse risk,[25] the global gene expression of the xenografted
leukemia is similar to the primary sample [26] and the xenograft’s in vivo response to dexa-
methasone correlated with patient outcome.[27]
Herein, we have demonstrated that there is no difference in the antileukemic efficacy of con-
tinuous and discontinuous dexamethasone regimens in the majority of murine and human
ALL models. All patients whose samples were used in this study remain in remission, including
the single patient whose ALL did show superior efficacy with continuous dexamethasone
(SJE2A007). These data indicate that for most pediatric ALL, discontinuous dexamethasone is
likely to be as effective as continuous dexamethasone; however, it is possible that for some ALL
cases, there may be inferior efficacy with discontinuous dexamethasone.
We have shown that the doses the mice received yielded comparable plasma dexamethasone
concentrations to those achieved in patients with ALL.[17] Dosing the dexamethasone in the
drinking water provides a level of systemic exposure that is similar to what the patients receive;
because of dexamethasone’s relatively long half-life, with doses split into two or three oral
doses per day, patients maintain near-constant plasma levels of drug during dexamethasone
pulses.[17, 28] Synthetic glucocorticoids such as dexamethasone suppress the release of natu-
rally occurring glucocorticoids: cortisol in humans, and corticosterone in mice. The mice
receiving continuous dexamethasone had nearly complete corticosterone suppression through-
out therapy, while the mice receiving discontinuous dexamethasone start producing corticoste-
rone while they are not receiving dexamethasone, although it does not reach the concentration
seen prior to treatment or in the untreated group of mice. Because cortisol suppression by glu-
cocorticoids in humans has been related to adverse effects such as growth suppression,[29, 30]
this may be a useful biomarker in studies of schedule-dependent glucocorticoid toxicity.
We have shown previously that age, gender, strain, and substrain (vendor) influence the
incidence of dexamethasone-induced osteonecrosis in mice, with the highest incidence in male
BALB/cJ mice started on treatment at 4 weeks of age.[17, 31] However, mice this young are not
optimal for evaluation of antileukemic efficacy. In our current study, because the mice were
older (8–12 weeks) when treatment started, and most had leukemia complicating evaluation of
bone histology at the time of sacrifice, they were not evaluable for osteonecrosis. The doses
used in this study (4 mg/L continuously vs 8 mg/L discontinuously) are exactly twice the doses
used in the young BALB/cJ mice for definitive osteonecrosis studies, which demonstrate that
continuous exposure is more osteonecrotic than discontinuous exposure; although these doses
produce osteonecrosis, they also cause morbidity and mortality from opportunistic infections
which precludes unbiased evaluations of osteonecrosis. The corticosterone recovery after 3.5
days off treatment was observed in both the NSG mice with leukemia treated with higher doses
and the young BALB/cJ mice treated with lower doses.[17]
Most of the xenograft samples were more resistant to dexamethasone ex vivo after in vivo
dexamethasone treatment, although this wasn’t the case for every sample, and some exhibited
minimal changes in LC50. We acknowledge that we may have selected different clones in the
xenograft samples than were present in the diagnosis sample through passaging in mice, lenti-
viral transduction, sorting, and dexamethasone treatment. Other investigators have used xeno-
grafts to demonstrate that ex vivo dexamethasone sensitivity and in vivo LFS correlate well,[32]
but clonal selection can occur in xenografts and influence dexamethasone sensitivity.[33, 34] It
is also possible the leukemia was epigenetically reprogrammed, which is one mechanism of glu-
cocorticoid resistance.[35–37] Nonetheless, most samples were equally sensitive to continuous
vs discontinuous dexamethasone post in vivo treatment. The start of treatment and duration
Discontinuous Dexamethasone Efficacy in ALL Xenografts
PLOS ONE | DOI:10.1371/journal.pone.0135134 August 7, 2015 13 / 18
varied by sample due to the variable time to engraftment and response to treatment (Table 1).
This might theoretically impact outcome by selecting more resistant clones with longer treat-
ment duration, however, we did not observe such an effect in our study.
For two T-ALL samples (SJTALL021916 and SJTALL033), there was a cyclical pattern in
the ventral luminescence, indicating that during the 3.5 days when the dexamethasone was
stopped, the cells grew very quickly, and when the mice were receiving dexamethasone, the
cells grew more slowly. When tested for ex vivo dexamethasone LC50, one sample
(SJTALL033) exhibited a higher LC50 after discontinuous than continuous treatment, and the
opposite was seen for the SJTALL021916 cells. Thus, although discontinuous dexamethasone
may permit cells time to recover between pulses, this did not necessarily result in more dexa-
methasone resistance.
Although discontinuous glucocorticoids have been used in many ALL regimens and for
many other diseases in an attempt to reduce adverse effects [38–46], there are almost no data
that compare disease efficacy in continuous versus discontinuous regimens. There has been
one clinical trial that randomized pediatric ALL patients to receive continuous vs discontinu-
ous dexamethasone during reinduction phases of therapy (CCG-1961), but the survival data
have been incompletely evaluated. Although the study suggests that there was no difference in
outcome between continuous and discontinuous dexamethasone in the context of an addi-
tional delayed intensification phase,[8, 15, 16] there has also been a suggestion that patients
who developed osteonecrosis had higher LFS by some [15] but not others.[3] Discontinuous
dexamethasone in post-induction therapy is now commonly used in clinical trials;[47–50]
however, it is not universally accepted,[51, 52] and daily glucocorticoids for four weeks remains
standard for most ALL induction regimens. Thus, it is highly relevant to compare the efficacy
of continuous versus discontinuous dexamethasone in and experimental model of ALL in
which the dexamethasone schedule can be systematically studied. Our results suggest there will
be equal efficacy of continuous and discontinuous dexamethasone for the majority of patients
with ALL.
Supporting Information
S1 Fig. Ventral luminescence in mice injected with SJMLL009 cells decreased during treat-
ment and increased when treatment was discontinued. Treatment was started at day 21 and
ended day 42 after injection of leukemia because the luminescence signal had decreased to
baseline levels. Treatment periods are indicated by the red and green boxes below the x-axis.
Green indicates discontinuous dexamethasone, red indicates continuous dexamethasone, and
blue indicates no dexamethasone. Each line represents one mouse.
(DOCX)
S2 Fig. In vitro sensitivity of murine BCR-ABL cell lines to dexamethasone. Blue indicates
BCR-ABL+ Arf-/- cells of the 129X1SvJ background, and red indicates BCR-ABL+ Arf-/- cells
on the C57BL/6 background. Sensitivity was tested with the MTS assay and LC50 was calcu-
lated using a four parameter logistic model (details in S1 Methods).
(DOCX)
S3 Fig. Luminescence at day 61 of mice injected with SJE2A007 cells shows that continuous
dexamethasone is more effective than discontinuous dexamethasone.Mice treated with no
dexamethasone are in the top row, mice in the discontinuous dexamethasone treatment group
are in the second and third rows, and mice in the continuous dexamethasone treatment group
are in the fourth and fifth rows. Images were acquired at 1 second exposure. The color scale
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was set to 5x107 – 2x109, and smoothing was set to 3x3 for each image.
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S1 Methods. Detailed methods of LC-MS assay of dexamethasone and corticosterone, ex
vivoMTT assay, and in vitroMTS assay.
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S1 Table. Patient demographics. All patients were treated on either the St. Jude Total XV or
XVI protocols and remain in remission. Risk Group classification has been described previ-
ously for Total XV [48] and XVI [49] protocols.
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